EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro-Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary Embolism

Alexander O'Hara, Jacob Pozin iD, Amir Darki, Fakiha Siddiqui iD, Debra Hoppensteadt iD, Jeanine Walenga iD, Jawed Fareed iD, Bulent Kantarcioglu iD

Clinical and Applied Thrombosis/Hemostasis · 2023

DOI: 10.1177/10760296231165058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, 2023. Verfasst von Alexander O'Hara und 7 weiteren Autor:innen. Beteiligte Einrichtung: Stritch School of Medicine, 2456Loyola University Chicago, Maywood, IL, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Pulmonary Embolism, Thrombosis, Carboxypeptidase B2. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type I and type II diabetes are closely associated with a pro-inflammatory state and to a pro-thrombotic state. The role of glycemic control in pulmonary embolism (PE) is poorly understood and requires additional investigation. The aim of this study is to investigate the relationship between glycemic control and thrombo-inflammatory biomarkers in a PE patient cohort compared to normal samples. Demographic and clinical information for 86 diabetic patients and 106 non-diabetic patients presenting with acute PE was collected via retrospective chart review. Plasma levels of pro-inflammatory (C-reactive protein [CRP], tumor necrosis factor-alpha [TNF-α], interleukin-6 [IL-6]) and pro-thrombotic (d-dimer, plasminogen activator inhibitor-1 [PAI-1], tissue plasminogen activator [tPA], thrombin activatable fibrinolysis inhibitor [TAFI], von-Willebrand factor [vWF], endogenous glycosaminoglycans [GAGs]) biomarkers were drawn within 24 hours of diagnosis of acute PE. Data was also obtained for a population of healthy adult controls. All the pro-inflammatory and pro-thrombotic biomarkers were elevated in diabetic PE patients in comparison to healthy controls. None of the biomarkers were elevated in diabetic PE patients when compared to non-diabetic PE patients. There was no difference in the levels of the pro-inflammatory biomarkers according to glycemic control. The plasma level of TAFI was elevated in diabetic patients with poor glycemic control. Diabetic patients were more likely to have a more severe PE. These studies demonstrate that thrombo-inflammatory biomarkers are elevated in diabetic PE patients with associated comorbidities in comparison to normal individuals. However, there is no difference between the PE cohort alone in comparison to PE with diabetes. The role of TAFI within the continuum of diabetic vascular disease warrants additional investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Pulmonary EmbolismThrombosisCarboxypeptidase B2AdultHumansTissue Plasminogen ActivatorRetrospective StudiesGlycemic ControlBiomarkersPlasminogen Activator Inhibitor 1Fibrinolysis

Stichwörter der Autor:innen

HbA1cTAFIdiabetes mellituspulmonary embolism

Substanzen

Tissue Plasminogen ActivatorBiomarkersPlasminogen Activator Inhibitor 1Carboxypeptidase B2

Autor:innen und Institutionen

  • Stritch School of Medicine, 2456Loyola University Chicago, Maywood, IL, USA.
  • Department of Cardiology, 25815Loyola University Medical Center, Maywood, IL, USA.
  • Department of Pathology and Laboratory Medicine, Cardiovascular Research Institute, 2456Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.
  • Program in Health Sciences, UCAM-Universidad Católica San Antonio de Murcia, Murcia, Spain.

ORCID-Profile: Jacob Pozin, Fakiha Siddiqui, Debra Hoppensteadt, Jeanine Walenga, Jawed Fareed, Bulent Kantarcioglu

Zitieren

APA

O'Hara, A., Pozin, J., Darki, A., Siddiqui, F., Hoppensteadt, D., Walenga, J., Fareed, J., & Kantarcioglu, B. (2023). Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro-Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary Embolism. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/10760296231165058

Vancouver

O'Hara A, Pozin J, Darki A, Siddiqui F, Hoppensteadt D, Walenga J, et al. Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro-Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary Embolism. Clinical and Applied Thrombosis/Hemostasis. 2023. doi:10.1177/10760296231165058

BibTeX
@article{OHara2023,
  author = {O'Hara, Alexander and Pozin, Jacob and Darki, Amir and Siddiqui, Fakiha and Hoppensteadt, Debra and Walenga, Jeanine and Fareed, Jawed and Kantarcioglu, Bulent},
  title = {Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro-Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary Embolism},
  journal = {Clinical and Applied Thrombosis/Hemostasis},
  year = {2023},
  doi = {10.1177/10760296231165058}
}
Kostenlos starten →